Timothy M. Palmer - Search Results

Year	Number of Results
2001	1
2002	2
2003	1
2004	2
2005	2
2006	2
2007	1
2008	2
2009	2
2010	1
2011	1
2012	6
2013	2
2014	2
2015	1
2016	3
2017	2
2018	4
2019	4
2020	1
2021	3
2022	2

1

Nutrient regulation of inflammatory signalling in obesity and vascular disease.

Palmer TM, Salt IP. Palmer TM, et al. Clin Sci (Lond). 2021 Jul 16;135(13):1563-1590. doi: 10.1042/CS20190768. Clin Sci (Lond). 2021. PMID: 34231841 Review.

2

Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.

Durham GA, Williams JJL, Nasim MT, Palmer TM. Durham GA, et al. Among authors: palmer tm. Trends Pharmacol Sci. 2019 May;40(5):298-308. doi: 10.1016/j.tips.2019.03.001. Epub 2019 Apr 2. Trends Pharmacol Sci. 2019. PMID: 30948191 Review.

3

Cavin-1: caveolae-dependent signalling and cardiovascular disease.

Williams JJ, Palmer TM. Williams JJ, et al. Among authors: palmer tm. Biochem Soc Trans. 2014 Apr;42(2):284-8. doi: 10.1042/BST20130270. Biochem Soc Trans. 2014. PMID: 24646232 Review.

4

The future of EPAC-targeted therapies: agonism versus antagonism.

Parnell E, Palmer TM, Yarwood SJ. Parnell E, et al. Among authors: palmer tm. Trends Pharmacol Sci. 2015 Apr;36(4):203-14. doi: 10.1016/j.tips.2015.02.003. Epub 2015 Mar 3. Trends Pharmacol Sci. 2015. PMID: 25744542 Free PMC article. Review.

5

Emerging roles of protein O-GlcNAcylation in cardiovascular diseases: Insights and novel therapeutic targets.

Bolanle IO, Riches-Suman K, Williamson R, Palmer TM. Bolanle IO, et al. Among authors: palmer tm. Pharmacol Res. 2021 Mar;165:105467. doi: 10.1016/j.phrs.2021.105467. Epub 2021 Jan 27. Pharmacol Res. 2021. PMID: 33515704 Review.

6

Revascularisation of type 2 diabetics with coronary artery disease: Insights and therapeutic targeting of O-GlcNAcylation.

Bolanle IO, Riches-Suman K, Loubani M, Williamson R, Palmer TM. Bolanle IO, et al. Among authors: palmer tm. Nutr Metab Cardiovasc Dis. 2021 May 6;31(5):1349-1356. doi: 10.1016/j.numecd.2021.01.017. Epub 2021 Feb 2. Nutr Metab Cardiovasc Dis. 2021. PMID: 33812732 Review.

7

Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation.

Salt IP, Palmer TM. Salt IP, et al. Among authors: palmer tm. Expert Opin Investig Drugs. 2012 Aug;21(8):1155-67. doi: 10.1517/13543784.2012.696609. Epub 2012 Jun 14. Expert Opin Investig Drugs. 2012. PMID: 22694351 Review.

8

Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor.

Milne GR, Palmer TM. Milne GR, et al. Among authors: palmer tm. ScientificWorldJournal. 2011 Feb 3;11:320-39. doi: 10.1100/tsw.2011.22. ScientificWorldJournal. 2011. PMID: 21298223 Free PMC article. Review.

9

Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?

Speirs C, Williams JJL, Riches K, Salt IP, Palmer TM. Speirs C, et al. Among authors: palmer tm. Pharmacol Res. 2018 Feb;128:88-100. doi: 10.1016/j.phrs.2017.10.001. Epub 2017 Oct 13. Pharmacol Res. 2018. PMID: 29037480 Review.

10

Regulation of the inflammatory response of vascular endothelial cells by EPAC1.

Parnell E, Smith BO, Palmer TM, Terrin A, Zaccolo M, Yarwood SJ. Parnell E, et al. Among authors: palmer tm. Br J Pharmacol. 2012 May;166(2):434-46. doi: 10.1111/j.1476-5381.2011.01808.x. Br J Pharmacol. 2012. PMID: 22145651 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results